Chief medical officer / svp clinical development (m/f/d)
ZürichSJP Biotec GmbH
...first-in-class Selective Translation Regulatory Inhibitor (STRI) platform powered to overcome treatment resistance in refractory cancers. Founded in 2024, SJP targets RAS-driven, hormone-receptor-positive, and immune-refractory tumors with a novel pipeline of small molecules developed in our [...]